118 related articles for article (PubMed ID: 8322284)
1. The effect of MCI-9042 on serotonin-induced platelet aggregation in type 2 diabetes mellitus.
Pietraszek MH; Takada Y; Taminato A; Yoshimi T; Watanabe I; Takada A
Thromb Res; 1993 Apr; 70(2):131-8. PubMed ID: 8322284
[TBL] [Abstract][Full Text] [Related]
2. Quantitative measurement of various 5-HT receptor antagonists on platelet activation induced by serotonin.
Qi R; Ozaki Y; Satoh K; Kurota K; Asazuma N; Yatomi Y; Kume S
Thromb Res; 1996 Jan; 81(1):43-54. PubMed ID: 8747519
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of serotonin-amplified human platelet aggregation by ketanserin, ritanserin, and the ergoline 5HT2 receptor antagonists-LY53857, sergolexole, and LY237733.
McBride PA; Mann JJ; Nimchinsky E; Cohen ML
Life Sci; 1990; 47(23):2089-95. PubMed ID: 2125095
[TBL] [Abstract][Full Text] [Related]
4. Role of 5-hydroxytryptamine in platelet thrombus formation and mechanisms of inhibition of thrombus formation by 5-hydroxytryptamine2A antagonists in rabbits.
Takano S
Arch Int Pharmacodyn Ther; 1995; 330(3):297-308. PubMed ID: 8836449
[TBL] [Abstract][Full Text] [Related]
5. Effects of sarpogrelate hydrochloride on platelet aggregation, and its relation to the release of serotonin and P-selectin.
Nakamura K; Kariyazono H; Moriyama Y; Toyohira H; Kubo H; Yotsumoto G; Taira A; Yamada K
Blood Coagul Fibrinolysis; 1999 Dec; 10(8):513-9. PubMed ID: 10636463
[TBL] [Abstract][Full Text] [Related]
6. Involvement of platelet-derived 5-hydroxytryptamine in thromboxane A2-induced aggregation in cat platelets.
Ogawa T; Sugidachi A; Asai F; Koike H
Blood Coagul Fibrinolysis; 1998 Apr; 9(3):233-40. PubMed ID: 9663705
[TBL] [Abstract][Full Text] [Related]
7. MCI-9042, a new antiplatelet agent is a selective S2-serotonergic receptor antagonist.
Hara H; Osakabe M; Kitajima A; Tamao Y; Kikumoto R
Thromb Haemost; 1991 Apr; 65(4):415-20. PubMed ID: 2057925
[TBL] [Abstract][Full Text] [Related]
8. A new method for assessment of an anti-5HT(2A) agent, sarpogrelate hydrochloride, on platelet aggregation.
Satoh K; Yatomi Y; Ozaki Y
J Thromb Haemost; 2006 Feb; 4(2):479-81. PubMed ID: 16420586
[No Abstract] [Full Text] [Related]
9. Blood serotonergic mechanisms in type 2 (non-insulin-dependent) diabetes mellitus.
Pietraszek MH; Takada Y; Takada A; Fujita M; Watanabe I; Taminato A; Yoshimi T
Thromb Res; 1992 Jun; 66(6):765-74. PubMed ID: 1519234
[TBL] [Abstract][Full Text] [Related]
10. Vitamin D diminishes the high platelet aggregation of type 2 diabetes mellitus patients.
Sultan M; Twito O; Tohami T; Ramati E; Neumark E; Rashid G
Platelets; 2019; 30(1):120-125. PubMed ID: 29313404
[TBL] [Abstract][Full Text] [Related]
11. Daily variations of platelet aggregation in relation to blood and plasma serotonin in diabetes.
Malyszko J; Urano T; Knofler R; Taminato A; Yoshimi T; Takada Y; Takada A
Thromb Res; 1994 Sep; 75(5):569-76. PubMed ID: 7992257
[TBL] [Abstract][Full Text] [Related]
12. Covalent complexes of albumin with serotonin, ketanserin and lysergic acid antagonize the activity of serotonin in human platelets.
VandenBerg SR; Gonias SL
Life Sci; 1989; 44(23):1777-85. PubMed ID: 2733551
[TBL] [Abstract][Full Text] [Related]
13. Characterization of rat platelet serotonin receptors with tryptamine agonists and the antagonists: ketanserin and SCH 23390.
Killam AL; Cohen ML
Thromb Res; 1991 Nov; 64(3):331-40. PubMed ID: 1805448
[TBL] [Abstract][Full Text] [Related]
14. Effects of sarpogrelate hydrochloride on adenosine diphosphate- or collagen-induced platelet responses in arteriosclerosis obliterans.
Nakamura K; Kariyazono H; Masuda H; Sakata R; Yamada K
Blood Coagul Fibrinolysis; 2001 Jul; 12(5):391-7. PubMed ID: 11505083
[TBL] [Abstract][Full Text] [Related]
15. Effects of ketanserin and mepyramine on platelet aggregation and on the uptake of 5-hydroxytryptamine into platelets.
Bevan J; Heptinstall S
Thromb Res; 1983 Jun; 30(5):415-23. PubMed ID: 6612677
[TBL] [Abstract][Full Text] [Related]
16. Long-term effects of erythropoietin on platelet serotonin storage and platelet aggregation in hemodialysis patients with reference to ketanserin treatment.
Borawski J; Rydzewski A; Pawlak K; Azzadin A; Buczko W; Mysliwiec M
Thromb Res; 1998 May; 90(4):171-80. PubMed ID: 9692616
[TBL] [Abstract][Full Text] [Related]
17. Effects of urapidil on 5-hydroxytryptamine induced platelet aggregation and on 14C-5-hydroxytryptamine uptake in platelets.
Storck J; Ochs JG; Kirsten R
Int J Clin Pharmacol Ther Toxicol; 1990 Jul; 28(7):303-8. PubMed ID: 2387654
[TBL] [Abstract][Full Text] [Related]
18. Serotonin-induced platelet aggregation predicts the antihypertensive response to serotonin receptor antagonists.
Gleerup G; Persson B; Hedner T; Winther K
Eur J Clin Pharmacol; 1993; 44(2):121-5. PubMed ID: 8453957
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological profiles of R-96544, the active form of a novel 5-HT2A receptor antagonist R-102444.
Ogawa T; Sugidachi A; Tanaka N; Fujimoto K; Asai F
Eur J Pharmacol; 2002 Dec; 457(2-3):107-14. PubMed ID: 12464356
[TBL] [Abstract][Full Text] [Related]
20. The effect of a 5HT2 receptor antagonist sarpogrelate (MCI-9042) treatment on platelet function in Buerger's disease.
Rydzewski A; Urano T; Hachiya T; Kaneko H; Baba S; Takada Y; Takada A
Thromb Res; 1996 Dec; 84(6):445-52. PubMed ID: 8987165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
